Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
862
Telavancin 10 mg/kg/day, IV for up to 14 days.
Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
Paradise Valley Hospital, 2400 E. 4th Street
National City, California, United States
Clinical Response
The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.
Time frame: 7-14 days following end of antibiotic treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.